Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Final Decision on Active Recommendation for HPV Vaccines Will Be Made at Next Subcommittee Meeting: Minister
January 23, 2014
- Revised PAL to Ensure Drug Safety to Take Effect in Late November
January 22, 2014
- Novartis Sales Rep Involvement in Investigator-Initiated Trial “Extremely Regrettable”: Health Minister Tamura
January 22, 2014
- No Hand Raised for Additional Applicant Appeal for New Flu Vaccine Project, Quota for 25 Million People in Limbo
January 21, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Prescribing of Torii’s Sublingual Cedar Pollinosis Treatment Cedartolen to be Restricted to Trained Doctors
January 21, 2014
- MHLW Approves Japan’s 1st SGLT-2 Inhibitor, Boehringer’s Anticancer Drug
January 20, 2014
- Public-Knowledge Based Applications Appropriate for Levonorgestrel, Methylprednisolone Sodium Succinate
January 20, 2014
- Mr Jo of EAD Criticizes Low Price Settlement Rates at Public Hospitals, Warns of Possible Reduction in Medical Fees
January 20, 2014
- PFSB Orders Distribution of Blue Letter on Bayer Yakuhin’s Dysmenorrhea Treatment YAZ Combination Tablets
January 20, 2014
- More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
- Chuikyo Approves General Proposal on Next Medical Fee Revision, Postpones Decision on Divided Dispensing
January 17, 2014
- Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
- PMDA Posts RMPs for Rheumatoid Arthritis Treatment Iguratimod
January 16, 2014
- PFSB Calls for Revision of Package Inserts for Diabetes Drugs Including Lyxumia
January 15, 2014
- PAFSC’s First Committee to Review Second SGLT-2 Inhibitor Dapagliflozin on Jan 24
January 15, 2014
- MHLW Begins Probe into Suspected Data-Tampering of J-ADNI Project
January 15, 2014
- MHLW to Decide Measures by March 2014 to Improve Price Settlement Rates: Ministry Official
January 14, 2014
- Diovan Scandal Could Undermine Confidence in Clinical Studies: Minister Tamura
January 14, 2014
- MHLW Proposes that Medical Institutions Clarify in Invoices that Consumption Tax Is Included in Drug Prices
January 14, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…